Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone study reveals hidden toll of hereditary angioedema

NCT ID NCT07448181

Knowledge-focused Sponsor: Istituti Clinici Scientifici Maugeri SpA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses smartphone surveys to track the real-life burden of hereditary angioedema (HAE) in 30 adults. Participants answer quick questions about their symptoms, mood, and daily activities every other day for 8 weeks. The goal is to capture day-to-day changes that standard questionnaires might miss, giving a clearer picture of how HAE truly affects people's lives.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal a more accurate picture of how hereditary angioedema affects daily life, potentially guiding better support and care strategies.
What could go wrong
This is a small, observational study with only 30 participants, so findings may not apply to everyone. It does not test any treatment, so it cannot directly improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study involves the participation of adult patients with a confirmed diagnosis of hereditary angioedema, belonging to the ITACA (Italian Network for Hereditary and Acquired Angioedema) national cohort and receiving follow-up care at the IRCCS Maugeri Milano (Via Camaldoli) center. Participation in the study is voluntary and subject to the signing of informed consent. Patients will complete the questionnaires independently via their own smartphones, with no requirement for in-person visits.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of Type 1 or Type 2 hereditary angioedema; * Age ≥ 18 years; * Ability to understand instructions and provide informed consent; * Ownership and proficiency in using a personal smartphone compatible with the m-Path application (Android or iOS); * Willingness to participate in the study for the entire duration of the observation period (8 weeks). Exclusion Criteria: * Diagnosis of acquired angioedema or other forms of angioedema unrelated to C1-inhibitor deficiency; * Severe cognitive or psychiatric disorders that compromise the ability to complete the questionnaires independently; * Age \< 18 years;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary angioedema - type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2 hereditary angioedema with C1Inh deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary angioedema - type 1 Hereditary angioedema - type 2 Hereditary angioedema with C1 esterase inhibitor deficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituti Clinici Scientifici Maugeri, Milan, Milan 20138

    RECRUITING

    Milan, 20138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.